Bjørn Holst

Bjørn Holst

Auto-generated profile, based on publicly available information

Bjørn Holst

Bioneer A/S, Hørsholm, Denmark

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Stem Cell Reports
Verified
Journal Article
Open access
MRMikkel A. Rasmussen
Mikkel A. Rasmussen
BHBjørn Holst
Bjørn Holst
Zeynep TümerZeynep Tümer
Zeynep Tümer
MJMads G. Johnsen
Mads G. Johnsen
SZShuling Zhou
Shuling Zhou
CCChristian Clausen
Christian Clausen
The discovery of human-induced pluripotent stem cells (iPSCs) has sparked great interest in the potential treatment of patients with their own in vitro differentiated cells. Recently, knockout of the Tumor Protein 53 (p53) gene was reported to facilitate reprogramming but unfortunately also led to genomic instability. Here, we report that transient suppression of p53 during nonintegrative reprogramming of human fibroblasts leads to a significant increase in expression of pluripotency markers and overall number of iPSC colonies, due to downstream suppression of p21, without affecting apoptosis and DNA damage. Stable iPSC lines generated with or without p53 suppression showed comparable expression of pluripotency markers and methylation patterns, displayed normal karyotypes, contained between 0 and 5 genomic copy number variations and produced functional neurons in vitro. In conclusion, transient p53 suppression increases reprogramming efficiency without affecting genomic stability, rendering the method suitable for in vitro mechanistic studies with the possibility for future clinical translation.

1 July 2000 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
BHBjørn Holst
Bjørn Holst
CLChristina Lunde
Christina Lunde
FLFernanda Lages
Fernanda Lages
RORui Oliveira
Rui Oliveira
CLCândida Lucas
Cândida Lucas
MKMorten Kielland-Brandt
Morten Kielland-Brandt
Many yeast species can utilize glycerol, both as a sole carbon source and as an osmolyte. In Saccharomyces cerevisiae, physiological studies have previously shown the presence of an active uptake system driven by electrogenic proton symport. We have used transposon mutagenesis to isolate mutants affected in the transport of glycerol into the cell. Here we present the identification of YGL084c, encoding a multimembrane‐spanning protein, as being essential for proton symport of glycerol into S. cerevisiae. The gene is named GUP1 (glycerol uptake) and, for growth on glycerol, is important as a carbon and energy source. In addition, in strains deficient in glycerol production it also provides osmotic protection by the addition of glycerol. Another open reading frame (ORF), YPL189w, presenting a high degree of homology to YGL084c, similarly appears to be involved in active glycerol uptake in salt‐containing glucose‐based media in strains deficient in glycerol production. Analogously, this gene is named GUP2. To our knowledge, this is the first report on a gene product involved in active transport of glycerol in yeasts. Mutations with the same phenotypes occurred in two other ORFs of previously unknown function, YDL074c and YPL180w.

1 March 2017 in Stem Cell Reports
Verified
Journal Article
Open access
YZYu Zhang
Yu Zhang
BSBenjamin Schmid
Benjamin Schmid
NNNanett K. Nikolaisen
Nanett K. Nikolaisen
MRMikkel A. Rasmussen
Mikkel A. Rasmussen
BABlanca Irene Aldana
Blanca Irene Aldana
KFKristine Freude
Kristine Freude
The truncated mutant form of the charged multivesicular body protein 2B (CHMP2B) is causative for frontotemporal dementia linked to chromosome 3 (FTD3). CHMP2B is a constituent of the endosomal sorting complex required for transport (ESCRT) and, when mutated, disrupts endosome-to-lysosome trafficking and substrate degradation. To understand the underlying molecular pathology, FTD3 patient induced pluripotent stem cells (iPSCs) were differentiated into forebrain-type cortical neurons. FTD3 neurons exhibited abnormal endosomes, as previously shown in patients. Moreover, mitochondria of FTD3 neurons displayed defective cristae formation, accompanied by deficiencies in mitochondrial respiration and increased levels of reactive oxygen. In addition, we provide evidence for perturbed iron homeostasis, presenting an in vitro patient-specific model to study the effects of iron accumulation in neurodegenerative diseases. All phenotypes observed in FTD3 neurons were rescued in CRISPR/Cas9-edited isogenic controls. These findings illustrate the relevance of our patient-specific in vitro models and open up possibilities for drug target development.

1 April 2017 in Stem Cell Research
Verified
Journal Article
Open access
PSPaul A. De Sousa
Paul A. De Sousa
RSRachel Steeg
Rachel Steeg
EWElisabeth Wachter
Elisabeth Wachter
KBKevin Bruce
Kevin Bruce
JKJason King
Jason King
TATimothy E. Allsopp
Timothy E. Allsopp
A fast track "Hot Start" process was implemented to launch the European Bank for Induced Pluripotent Stem Cells (EBiSC) to provide early release of a range of established control and disease linked human induced pluripotent stem cell (hiPSC) lines. Established practice amongst consortium members was surveyed to arrive at harmonised and publically accessible Standard Operations Procedures (SOPs) for tissue procurement, bio-sample tracking, iPSC expansion, cryopreservation, qualification and distribution to the research community. These were implemented to create a quality managed foundational collection of lines and associated data made available for distribution. Here we report on the successful outcome of this experience and work flow for banking and facilitating access to an otherwise disparate European resource, with lessons to benefit the international research community. ETOC: The report focuses on the EBiSC experience of rapidly establishing an operational capacity to procure, bank and distribute a foundational collection of established hiPSC lines. It validates the feasibility and defines the challenges of harnessing and integrating the capability and productivity of centres across Europe using commonly available resources currently in the field.

1 November 2016 in Stem Cell Research
Verified
Journal Article
Open access
APAnna Poon
Anna Poon
BSBenjamin Schmid
Benjamin Schmid
CPCarlota Pires
Carlota Pires
TNTroels T. Nielsen
Troels T. Nielsen
LHLena E. Hjermind
Lena E. Hjermind
KFKristine Freude
Kristine Freude
Mutations in the presenilin 1 (PSEN1) gene lead to the most aggressive form of familial Alzheimer's disease (AD). Human induced pluripotent stem cells (hiPSCs) derived from AD patients and subsequently differentiated can be used for disease modeling. We have previously generated a hiPSC line from a familial AD patient carrying a L150P point mutation in PSEN1. Here we used CRISPR/Cas9 gene editing to correct for the single base pair mutation. This gene-corrected line, L150P-GC-hiPSC, serves as an isogenic control to the mutant line for future investigation of mechanisms and cellular phenotypes altered by this specific PSEN1 mutation.

1 June 2005 in Biomaterials
Verified
Journal Article
Closed access
TBThomas Brevig
Thomas Brevig
BHBjørn Holst
Bjørn Holst
ZAZahida Ademovic
Zahida Ademovic
NRNoemi Rozlosnik
Noemi Rozlosnik
JRJette H. Røhrmann
Jette H. Røhrmann
PKPeter Kingshott
Peter Kingshott